Contact
searchSearch
HMP Global
Login

GPRC5D Quiz

Quiz
Quiz: Where is the GPRC5D Gene Expressed?
03/23/2023
True or False: The GPRC5D gene is typically expressed in hair follicles, but CD138-positive multiple myeloma cells have also been found to express GPRC5D.
True or False: The GPRC5D gene is typically expressed in hair follicles, but CD138-positive multiple myeloma cells have also been found to express GPRC5D.
True or False: The GPRC5D gene...
03/23/2023
Oncology
Quiz
Quiz: Principles Behind Choosing Optimal Therapeutic Agent Combinations for Patients With MM
03/20/2023
According to Dr Faith E. Davies, MD, which of the following is NOT a principle behind selecting an optimal combination of therapeutic agents for patients with multiple myeloma in the early relapse stage?
According to Dr Faith E. Davies, MD, which of the following is NOT a principle behind selecting an optimal combination of therapeutic agents for patients with multiple myeloma in the early relapse stage?
According to Dr Faith E. Davies,...
03/20/2023
Oncology

Recent News

News
Lorlatinib Shows Real-World Promise in in ALK-Positive Non-Small Cell Lung Cancer
04/24/2026
Emily Estrada
Real-world data demonstrate that lorlatinib provides high response and durable disease control in advanced ALK-positive NSCLC, with exploratory lipid biomarkers potentially predicting response.
Real-world data demonstrate that lorlatinib provides high response and durable disease control in advanced ALK-positive NSCLC, with exploratory lipid biomarkers potentially predicting response.
Real-world data demonstrate that...
04/24/2026
Oncology
News
Mirvetuximab Plus Carboplatin Demonstrates Promise in Platinum-Sensitive Ovarian Cancer
04/21/2026
Stephanie Holland
Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows clinical promise in FRα-expressing platinum-sensitive ovarian cancer.
Results from the phase 2 IMGN853-0420 study demonstrate that mirvetuximab soravtansine plus carboplatin shows clinical promise in FRα-expressing platinum-sensitive ovarian cancer.
Results from the phase 2...
04/21/2026
Oncology
News
Mocertatug Rezetecan Shows Promising Efficacy, Manageable Safety in Ovarian and Endometrial Cancer
04/21/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 study demonstrate that mocertatug rezetecan shows clinical promise among patients with platinum-resistant ovarian cancer and recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 study demonstrate that mocertatug rezetecan shows clinical promise among patients with platinum-resistant ovarian cancer and recurrent endometrial cancer.
Results from the phase 1...
04/21/2026
Oncology
News
Camizestrant Plus Capivasertib Shows Promise in ER-Positive, HER2-Negative Advanced Breast Cancer
04/17/2026
Emily Estrada
Results from the SERENA-1 trial demonstrate that camizestrant plus capivasertib shows strong clinical promise in endocrine-resistant patients with ER-positive, HER2-negative advanced breast cancer.
Results from the SERENA-1 trial demonstrate that camizestrant plus capivasertib shows strong clinical promise in endocrine-resistant patients with ER-positive, HER2-negative advanced breast cancer.
Results from the SERENA-1 trial...
04/17/2026
Oncology
News
R-CHOP-Like Therapy Retreatment Yields Durable Responses in Late-Relapsing Diffuse Large B-Cell Lymphoma
04/17/2026
Emily Estrada
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with...
04/17/2026
Oncology
News
LB-100 Plus Dostarlimab Shows Clinical Promise in Platinum-Resistant Ovarian Clear Cell Carcinoma
04/15/2026
Emily Estrada
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase...
04/15/2026
Oncology
News
Longitudinal ctDNA Clearance Predicts Outcomes in Advanced Ovarian Cancer
04/15/2026
Emily Estrada
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective...
04/15/2026
Oncology
News
Chemotherapy Followed by Letrozole Maintains Advantage Over Letrozole Alone in Low-Grade Serous Carcinoma
04/14/2026
Stephanie Holland
Results from the phase 3 NRG-GY019 trial confirm that letrozole alone is inferior to chemotherapy followed by letrozole among patients with low-grade serous carcinomas.
Results from the phase 3 NRG-GY019 trial confirm that letrozole alone is inferior to chemotherapy followed by letrozole among patients with low-grade serous carcinomas.
Results from the phase 3...
04/14/2026
Oncology
News
Relacorilant Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
04/13/2026
Stephanie Holland
Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.
Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.
Final overall survival results...
04/13/2026
Oncology
News
Maintenance Carfilzomib Plus Lenalidomide and Dexamethasone Following Autologous HSCT for Newly Diagnosed Multiple Myeloma
04/10/2026
Stephanie Holland
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS...
04/10/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use